Emisphere Technologies (EMIS) Stock Price, News & Analysis

Company Overview

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

Key Stats

• Today's Range: $7.81 to $7.81
• 50-Day Range: $7.81 to $7.81
• 52-Week Range: $4.06 to $9.16
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EMIS Stock Analysis - Frequently Asked Questions

How have EMIS shares performed this year?

Emisphere Technologies' stock was trading at $7.81 on January 1st, 2025. Since then, EMIS stock has increased by 0.0% and is now trading at $7.81.

How were Emisphere Technologies' earnings last quarter?

Emisphere Technologies Inc. (OTCMKTS:EMIS) announced its earnings results on Friday, May, 12th. The company reported $0.04 earnings per share (EPS) for the quarter. The firm had revenue of $0.22 million for the quarter.

How do I buy shares of Emisphere Technologies?

Shares of EMIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Emisphere Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emisphere Technologies investors own include Novo Nordisk A/S (NVO), Fulcrum Therapeutics (FULC), VIVUS (VVUS), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA) and Capricor Therapeutics (CAPR).

Company Calendar

• Last Earnings: 5/12/2017
• Today: 8/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EMIS
• CIK: 805326
• Web: www.emisphere.com
• Phone: 973-532-8000
• Fax: 973-422-0125
• Employees: 6
• Year Founded: 1986

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A